Translatum Moves Forward, Plans to Engage FDA

Shelley Boyd, MD, president and chief scientific officer, says Translatum Medicus Inc. has raised its first angel round based upon the potential of the company’s macrophage modulator for the treatment of blinding eye disease. Translatum is about to initiate dialogue with the FDA to pursue a clinical regimen. TMI and a related company Tracery both were chosen to be part of Johnson & Johnson Innovation (JLabs) in Toronto.

The company’s lead drug candidate TMi-018, demonstrated suitable for sustained delivery, is anticipated to be efficacious alone and in combination therapy across all genotypes for the treatment of dry AMD.